TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Working to Implement and Sustain Digital Outcome Measures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Participants for this project will fall into four groups: 1) clinic executives and upper leaders (i.e., Chief Executive Officer, Executive Directors, program administrators, n=20), 2) clinic first-level leaders (i.e. clinical supervisors, n=20), 3) clinicians serving children with emotional and behavioral disorders (n=120), and 4) caregivers of children with emotional and behavioral disorders who receive outpatient mental health services within participating clinics (n=720). Caregivers will be recruited in two distinct cohorts of 360 each.~Inclusion criteria for all groups of participants are intentionally broad in line with the pragmatic nature of the trial.~Inclusion Criteria for Clinics~1. Provide outpatient psychotherapy services to children ages 4 to 18 who have emotional and/ or behavioral disorders and their families~2. Have at least 3 full time equivalent clinicians on staff~3. Not currently implementing a digital measurement-based care system clinic wide~Inclusion Criteria for Executives and Upper Leaders~1. Identified as Chief Executive Officer, Executive Director, or high-level administrator at an enrolled clinic~Inclusion Criteria for first-level leaders~1. Identified as a clinical supervisor or clinical work-group supervisor/ leader at an enrolled clinic~Inclusion Criteria for Clinicians~1. Employed as staff at participating clinic~2. Provides outpatient mental health services (psychotherapy) to youth clients~Inclusion Criteria for Caregivers of Youth Who Receive Services at Participating Clinics~1. Child is ages 4 to 18 years at intake,~2. Child has been diagnosed with an emotional or behavioral disorder by clinic staff~3. Clinical staff at the site determined that the youth's treatment needs can be appropriately addressed by the clinic

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- LOCI (Intervention) (Type: EXPERIMENTAL): In clinics assigned to the LOCI condition, executives and first-level leaders will receive leadership training and coaching to support implementation of the OQ-A system. In addition, leaders and clinicians in this condition will receive training and technical assistance to implement the OQ-A measurement-based care system.
- Training and Technical Assistance only (Control) (Type: ACTIVE_COMPARATOR): In clinics assigned to the control group, leaders and clinicians will receive training and technical assistance to implement the OQ-A measurement-based care system. In addition, to support enrollment in this condition, leaders in this condition will be offered access to general web-based leadership seminars.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent~* At least 6 months history of Gastroesophageal reflux disease (GERD) symptoms~* Continuous treatment with Proton Pump Inhibitor (PPI)~* Ability to read and write~Exclusion Criteria:~* Prior surgery of the upper gastrointestinal (GI) tract~* History of clinically significant diseases other than GERD~* Need for concomitant medication with drugs that may influence gastrointestinal symptoms

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males or females at least 18 years of age with non-diabetic proteinuric renal diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rasagiline Tablets Special Drug Use-Results Survey Survey on Long-term Safety

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~-Patients with Parkinson's disease should be surveyed.~Exclusion Criteria:~-Participants who have contraindications on package insert of rasagiline.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rasagiline 1 mg (Type: None): Rasagiline 1 milligram (mg), orally, once daily for up to 24 months. Participants received interventions as part of routine medical care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic plaque psoriasis with disease duration of at least 6 months~* Sub-optimal response to treatment with etanercept, methotrexate, or narrow-band UVB phototherapy~Exclusion Criteria:~* Prior treatment with adalimumab~* Multiple concomitant therapy restrictions and/or washouts (topicals, ultraviolet, other systemic psoriasis therapies)~* Prior treatment with natalizumab~* Concurrent active skin diseases/infections~* Poorly controlled medical conditions~* History of neurologic symptoms suggestive of central nervous system (CNS) demyelinating disease~* History of certain cancers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open Label (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation Of Sperm Production With Healthy Male Volunteers Receiving Lyrica Or Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy 18 to 55 years old males~Exclusion Criteria:~* Screening sperm count \<20 x 106/mL; screening sperm motility \<50% motile (a+b) or \<25% Class a motile or screening sperm morphology \<30% normal or semen volume \<1.5 mL or white blood cell count \>1 x 106 /mL on any screening visit sample

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Exenatide for Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Parkinson's disease.~* Males or Females.~* Hoehn and Yahr stage ≤ 2.5 in the On medication state.~* Between 25 and 75 years of age.~* On dopaminergic treatment with wearing off phenomena.~* Ability to self-administer, or to arrange carer administration of trial drug.~* Documented informed consent to participate.~Exclusion Criteria:~* Diagnosis or suspicion of other cause for parkinsonism.~* Body mass index \<18.5.~* Known abnormality on CT or MRI brain imaging considered likely to compromise compliance with trial protocol/DaTSCAN acquisition.~* Concurrent dementia defined by a score lower than 120 on the Mattis Dementia Rating Scale.~* Concurrent severe depression defined by a score \>16 on the MADRS.~* Prior intra-cerebral surgical intervention for Parkinson's disease.~* Already actively participating in a trial of a device, drug or surgical treatment for Parkinson's disease.~* Severe gastrointestinal disease (e.g. gastroparesis).~* Previous exposure to Exenatide.~* Severely impaired renal function with creatinine clearance \<30ml/min.~* History of pancreatitis.~* Hyperlipidaemia.~* History or suspicion of thyroid cancer~* Known or suspected intolerance of DaTSCAN or Potassium Iodide administration.~* Females that are pregnant or breast feeding.~* Participants who lack the capacity to give informed consent~* Any medical or psychiatric condition which in the investigator's opinion compromises the potential participant's ability to participate.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: ACTIVE_COMPARATOR): Bydureon- 2mg administered subcutaneously once weekly
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, 2mg administered subcutaneously once weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mindfulness Meditation as a Rehabilitation Strategy for Persons With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with SCID I confirmed DSM-iV diagnosis of schizophrenia or schizoaffective disorder~* in a post acute phase of illness defined by no hospitalizations or changes in type of psychotropic medication or place of residence in the past 30 days~* who are either already enrolled in vocational rehabilitation and working or willing to enroll in vocational rehabilitation and begin working~Exclusion Criteria:~* history of mental retardation~* active substance abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Mindfulness Meditation
- Arm 2 (Type: ACTIVE_COMPARATOR): Support Group that involves discussion of work-related issues in which participants are facilitated to assist each other with problem solving and offer support

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* have type 2 diabetes and are treated with diet and exercise alone.~* at least 18 years of age.~* HbA1c between 7.1% and 11.0%, inclusive.~* Body mass index (BMI) of 23 kg/m2 to 45 kg/m2, inclusive.~* Have a history of stable body weight (not varying by \>5% for at least 3 months prior to screening).~Exclusion Criteria:~* Have history of cardiac disease or presence of active cardiac disease within the year prior to inclusion in the study including myocardial infarction, clinically significant arrhythmia, unstable angina, moderate to severe congestive heart failure, coronary artery bypass surgery, or angioplasty~* Have a history of renal transplantation or are currently receiving renal dialysis~* Have active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years.~* Have history of severe GI disorder (e.g., gastroparesis)~* Have a history of acute or chronic pancreatitis.~* Have active proliferative retinopathy.~* Have been treated with drugs that promote weight loss (e.g., Xenical®\[orlistat\], Meridia® \[sibutramine\], Acomplia® \[rimonabant\], Acutrim® \[phenylpropanolamine\], or similar over-the-counter medications) within 3 months of screening.~* Have been treated with any antidiabetic agent for more than 7 days within 3 months prior to screening.~* Have had an organ transplant.~* Have previously completed or discontinued study drug in this study, withdrawn from this study or any other study investigating exenatide once weekly.~* Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.~* Are currently enrolled in any other clinical study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exenatide Once Weekly (Type: EXPERIMENTAL): None
- Metformin (Type: ACTIVE_COMPARATOR): None
- Sitagliptin (Type: ACTIVE_COMPARATOR): None
- Pioglitazone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Insulin Detemir With NPH Insulin in Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes~* Currently on basal-bolus regimen~* BMI = 35.0 kg/m2~* HbA1c =11.0%~Exclusion Criteria:~* Proliferative retinopathy or maculopathy~* Recurrent major hypoglycaemia~* Cardial problems~* Uncontrolled hypertension~* Impaired hepatic or renal function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Early Two-dose Measles Vaccination Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Infants of 4½ months of age registered in the Bandim Health Project registration system and currently living in the Bandim Health Project areas: Bandim I, Bandim II, Belem, Mindará and Cuntum; and who received all three diphtheria-tetanus-pertussis vaccinations at least 4 weeks before enrollment~Exclusion Criteria:~* Severe illness requiring immediate hospitalisation

- Gender: ALL
- Minimum Age: 4 Months
- Maximum Age: 6 Months
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Standard titre Edmonston-Zagreb measles vaccine at 4½ and 9 months of age
- 2 (Type: ACTIVE_COMPARATOR): Standard titre Schwarz measles vaccine at 9 months of age
- 3 (Type: ACTIVE_COMPARATOR): Standard titre Edmonston-Zagreb measles vaccine at 9 months of age

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Double-blind Trial to Investigate Efficacy and Tolerance of Ambroxol Lozenges 20 mg in Sore Throat

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
1. Patients having a sore throat with acute viral pharyngitis. 2. Female and male ambulant patients between the ages of 18 and 65. 3. The throat pain intensity is rated at least severe on the VRS (PI). 4. Written Informed Consent is given by the patient. 5. Compliance by the patient seems guaranteed.~1. Patients with symptoms of primarily bacterial pharyngitis or bacterial secondary infection (clinical findings; inter alia assessment of exudate).~2. First indication of symptoms of acute pharyngitis (e.g., sore throat) occurred more than 3 days ago already.~3. Counting of white blood cell in blood routine examination exceeds 10?109/L.~4. Patients who suffered from acute viral or bacterial pharyngitis in the past 4 weeks.~5. Broncho-motor disorders or concomitant diseases with relatively large quantities of secretion (danger of secretion blockage).~6. Known hypersensitivity to Ambroxol or to auxiliary substances contained in the tablet.~7. Previous and/or existing tumour condition.~8. Pregnancy and/or breast-feeding.~9. Alcohol, and/or drug abuse.~10. Simultaneous participation in another clinical trial.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): None
- Ambroxol (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented physician-diagnosed asthma for at least 12 months prior to Visit 1.~* Morning pre-bronchodilator FEV1 (Forced expiratory volume) of \> 50% predicted normal value at Visit 1 or Visit 2.~* Body weight ≥ 40 kg.~* For women of childbearing potential, a negative urine pregnancy test is required prior to administration of study intervention at Visit 3.~* Must have 'not well-controlled' asthma.~Exclusion Criteria:~* Clinically important pulmonary disease other than asthma.~* Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment.~* Life-threatening asthma~* History of cancer.~* Allergy to eggs, if egg based influenza vaccine will be administered.~* History of anaphylaxis to any biologic therapy.~* Current smokers or participants with smoking history ≥ 10 pack-years and participants using vaping products, including electronic cigarettes. Former smokers with a smoking history of \< 10 pack-years and users of vaping or e-cigarette products must have stopped for at least 6 months prior to Visit 1 to be eligible.~* History of alcohol or drug abuse within 12 months prior to the date of informed consent.~* Major surgery within 8 weeks prior to Visit 1 or planned surgical procedures during the conduct of the study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Tezepelumab (Type: EXPERIMENTAL): Participants will be randomized to receive tezepelumab 210 mg administered at Weeks 0, 4, 8 and 12. Participants will also receive a single dose of inactivated quadrivalent seasonal influenza vaccine intramuscularly at Week 12, prior to the fourth dose of study intervention.
- Placebo to Tezepelumab (Type: PLACEBO_COMPARATOR): Participants will be randomized to receive placebo SC Q4W, administered at Weeks 0, 4, 8 and 12. Participants will also receive a single dose of inactivated quadrivalent seasonal influenza vaccine intramuscularly at Week 12, prior to the fourth dose of study intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject understands the study procedures and agrees to participate in the study by giving written informed consent.~* Subject is 18 years of age or older.~* Subject agrees to not participate in another study of an investigational agent during the study.~* Subject must be receiving hemodialysis 3 times weekly for at least 3 months~* Other Inclusion Criteria may apply~Exclusion Criteria:~* Currently receiving treatment in another investigational device or drug study, or ended treatment on another investigational device or drug study(s) within 8 weeks prior to screening.~* Other investigational procedures while participating in this study are excluded.~* Anticipated or scheduled parathyroidectomy during the study period.~* Subject has received a parathyroidectomy within 3 months prior to dosing.~* Anticipated or scheduled kidney transplant during the study period.~* Subject has known sensitivity to any of the products or components to be administered during dosing.~* Subject has participated in a prior clinical trial of AMG 416~* Subject has an unstable medical condition based on medical history, physical examination, and routine laboratory tests, or is otherwise unstable in the judgment of the Investigator.~* Subject has a history of any illness that, in the opinion of the Investigator, might confound the results of the study or pose additional risk to the subject.~* Other Exclusion Criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo administered by intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks.
- Etelcalcetide (Type: EXPERIMENTAL): Participants received etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW for 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete